The ixodes scapularis ticks that flourish throughout many areas in the U.S. are perfect hosts for not just Bb sensu strictu, aka conventional Lyme, but also are excellent reservoirs for both B. garinii and B. afzelii. Which begs the question: Why aren't U.S. health surveillance agencies regularly testing for the latter two species? We know that many parts of Europe can and do sift for all three of the sensu lato family.
In fact, you would think at this stage, not only would tests distinguish between species, but also determine strains since virulence can be tied into strain, just are purportedly it is to species.
Now, testing around the world is rushing to catch up with the unexpected and widespread - at least in terms of continents - emergence of B. miyamotoi, which darkens further the pathogen mix. Without a good test yet, although labs like Imugen are working on the problem, how can we tell how deep this TBD has burrowed into communities that just 24 months ago were told were safe from it? And how many are ill with it, and are jettisoned out of medical communities with the label of diagnosis unknown since current tests cannot define it?
This is representative of the broad and long-standing practice of foisting TBD patients into the ME/CFS community. Moreover, it muddies the picture on how great or small the differences are between those two theoretical distinct maladies.
In fact, you would think at this stage, not only would tests distinguish between species, but also determine strains since virulence can be tied into strain, just are purportedly it is to species.
Now, testing around the world is rushing to catch up with the unexpected and widespread - at least in terms of continents - emergence of B. miyamotoi, which darkens further the pathogen mix. Without a good test yet, although labs like Imugen are working on the problem, how can we tell how deep this TBD has burrowed into communities that just 24 months ago were told were safe from it? And how many are ill with it, and are jettisoned out of medical communities with the label of diagnosis unknown since current tests cannot define it?
This is representative of the broad and long-standing practice of foisting TBD patients into the ME/CFS community. Moreover, it muddies the picture on how great or small the differences are between those two theoretical distinct maladies.
Last edited by a moderator: